Qiao Li, Fabian Pfersdorf, Fernando Salgado-Polo, Martin Gustavsson
{"title":"Mechanisms of XCR1 Membrane Trafficking and Constitutive Endocytosis","authors":"Qiao Li, Fabian Pfersdorf, Fernando Salgado-Polo, Martin Gustavsson","doi":"10.1111/bcpt.70318","DOIUrl":"10.1111/bcpt.70318","url":null,"abstract":"<p>Chemokines orchestrate immune cell trafficking through receptor-mediated signalling and are implicated in inflammatory, autoimmune and neuropathic disorders. The XCL1–XCR1 axis is of particular interest because XCR1 is selectively expressed on mature conventional type 1 dendritic cells (cDC1s), where it supports communication with activated CD8<sup>+</sup> T cells and NK cells and promotes antigen cross-presentation. This selectivity has made XCR1 an attractive target for dendritic cell–based cancer vaccines, while emerging evidence also links XCL1–XCR1 signalling to neuroinflammation and pain. Despite its therapeutic potential, the mechanisms governing XCR1 activation and trafficking remain understudied. Here, we characterize XCR1 expression, membrane trafficking, and basal internalization to define mechanisms that may influence therapeutic targeting. We show that XCR1 undergoes constitutive internalization through a β-arrestin–independent but adaptor protein 2 (AP2)–dependent pathway, distinguishing it from other chemokine receptors with constitutive endocytosis. Furthermore, we identify specific sequence motifs critical for its subcellular localization and intracellular trafficking. These findings provide new mechanistic insights into XCR1 regulation and may inform the development of targeted therapeutics and antigen-delivery strategies in cancer and inflammation.</p>","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"139 5","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13655292/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149164578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Thomas Leth Jensen, Sanne Møller Thysen, Espen Jimenez-Solem, Anders Jørgensen, Camilla Bjørn Jensen, Hans Kristian Råket, Merete Osler, Mads Nielsen, Lars Christian Lund
{"title":"Investigating Potential Adverse Drug Reactions of Lisdexamfetamine Using Sequence Symmetry Analysis","authors":"Thomas Leth Jensen, Sanne Møller Thysen, Espen Jimenez-Solem, Anders Jørgensen, Camilla Bjørn Jensen, Hans Kristian Råket, Merete Osler, Mads Nielsen, Lars Christian Lund","doi":"10.1111/bcpt.70316","DOIUrl":"10.1111/bcpt.70316","url":null,"abstract":"<p>The prevalence of ADHD is increasing rapidly, and lisdexamfetamine is increasingly popular, but few studies investigate its safety. We performed a sequence symmetry analysis (SSA) using Danish register data to identify potential ADRs associated with lisdexamfetamine in 2013–2023. Outcomes were incident prescriptions or incident discharge diagnoses. We calculated trend-adjusted sequence ratios (SR) with 95% confidence intervals (CI). We additionally performed two comparator SSAs for the same outcomes following incident use of stimulants (methylphenidate and dexamfetamine) or non-stimulants (guanfacine and atomoxetine). This study is reported according to RECORD-PE guidelines. We included 48 740 incident lisdexamfetamine users with a median age of 24 years (IQR 16–35). SRs were calculated for 1426 exposure–diagnosis and 1337 exposure–prescription pairs. The 50 highest SRs from each category were evaluated. Among these, 28 exposure–outcome combinations had a 95% CI lower bound above 1. Of the 100 outcomes, 33 were considered known ADRs, while 60 were previously unknown. Two outcomes indicating increased urinary symptoms were identified (‘hematuria’, SR: 1.88 [95% CI: 1.25; 2.85] and ‘other urinary symptoms’, SR: 1.63 [1.20; 2.23]). We also identified serious gastrointestinal outcomes as a potential safety alert. Further investigation into these symptoms as potential ADRs is warranted.</p>","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"139 5","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bcpt.70316","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149134943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Vitamin D: Physiology, Pharmacology and Clinical Evidence for Supplementation—A Narrative Review","authors":"Jyrki K. Virtanen","doi":"10.1111/bcpt.70315","DOIUrl":"10.1111/bcpt.70315","url":null,"abstract":"<p>Vitamin D is a nutrient and prohormone obtained from diet and supplements and synthesized in the skin. It is essential for calcium and phosphate homeostasis and skeletal health and influences multiple extra-skeletal processes, yet deficiency remains common worldwide. This narrative review summarizes vitamin D sources, physiology, metabolism, pharmacokinetics, clinical relevance and safety and outlines the distinct pharmacokinetic profiles and clinical roles of vitamin D, calcidiol and calcitriol and its analogues. Evidence consistently supports vitamin D, combined with calcium, for preventing and treating deficiency-related skeletal disorders in high-risk populations, and in specific conditions such as malabsorption, chronic kidney disease, hypoparathyroidism and frailty. In vitamin D–replete populations, large trials show limited extra-skeletal benefits, apart from modest effects on cancer mortality and progression from prediabetes to Type 2 diabetes. Untargeted screening is not recommended. Future research should prioritize targeted supplementation, standardized assays and identification of populations most likely to benefit from supplementation.</p>","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"139 5","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bcpt.70315","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149134932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alex Luiz Menezes da Silva, Luiz Gustavo dos Reis de Freitas, Akira Otake Hamoy, Clarissa Araujo da Paz, Luan Oliveira Ferreira, Esther Padilha da Silveira, Maria Klara Otake Hamoy, Nilton Akio Muto, Dielly Catrina Favacho Lopes, Moisés Hamoy
{"title":"High Doses of N-Acetyl-P-Aminophenol Cause Acute Changes in Electroencephalographic and Electrocardiographic Activities in Wistar Rats","authors":"Alex Luiz Menezes da Silva, Luiz Gustavo dos Reis de Freitas, Akira Otake Hamoy, Clarissa Araujo da Paz, Luan Oliveira Ferreira, Esther Padilha da Silveira, Maria Klara Otake Hamoy, Nilton Akio Muto, Dielly Catrina Favacho Lopes, Moisés Hamoy","doi":"10.1111/bcpt.70321","DOIUrl":"10.1111/bcpt.70321","url":null,"abstract":"<p><i>N</i>-acetyl-<i>p</i>-aminophenol (APAP), or acetaminophen, is the most prescribed analgesic and antipyretic, even used in association with other drugs. Because it is easily bought in drugstores, much evidence about its toxic effects is known due to high doses or continuous use, which can lead to death in cases of intoxication. The present study aimed demonstrate the ability of APAP to change the brain and heart electrical activities, as early as significant increase in liver enzymes. Thus, a toxic dose of 1 g/kg was administered orally, and the animals were assessed every 3 h until 12 h for electroencephalography, electrocardiography and liver function data. The results showed that a toxic dose of APAP was capable of reducing brain electrical activity for the delta, theta, beta and gamma waves; however, the alpha wave activity was increased. In the heart, a reduced electrical activity was observed synchronously with the electroencephalogram. During the 12-h follow-up period, a significant increase in liver enzymes was observed. Taken together, we conclude that high doses of APAP can alter frequency brain oscillations and promote cardiac changes independently of liver damage in the first 12 h.</p>","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"139 5","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bcpt.70321","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149134924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Grietje van Elp, Maikel Borg, Jens H. J. Bos, Catharina C. M. Schuiling-Veninga, Katja Taxis, Frank G. A. Jansman
{"title":"Frequency of Clinically Relevant Drug–Drug Interactions Between Tyrosine Kinase Inhibitors and Proton Pump Inhibitors in Patients With Cancer Using Real-World Data","authors":"Grietje van Elp, Maikel Borg, Jens H. J. Bos, Catharina C. M. Schuiling-Veninga, Katja Taxis, Frank G. A. Jansman","doi":"10.1111/bcpt.70317","DOIUrl":"10.1111/bcpt.70317","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Proton pump inhibitors (PPIs) raise stomach pH, leading to reduced bioavailability of many tyrosine kinase inhibitors (TKIs), thereby affecting treatment outcomes. To what extent this interaction occurs in clinical practice remains underexplored.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To determine the frequency of clinically relevant interactions between TKIs and PPIs in clinical practice and the duration of concomitant prescription.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A retrospective observational study was performed using the IADB.nl prescription database. Clinically relevant drug–drug interactions between TKIs and PPIs were assessed using four drug compendia (i.e., KNMP Kennisbank, Health Base, Lexidrug and Merative Micromedex). Patients who were prescribed a TKI and PPI with a clinically relevant DDI concomitantly, between 1 January 2013 and 31 December 2024, were included. Concomitant prescription was defined as ≥ 7 days of simultaneous prescription.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Findings</h3>\u0000 \u0000 <p>In total, 60 TKIs were registered in the Netherlands; 19 TKIs had clinically relevant interactions reported by at least one compendium. Overall, 393 of 1759 (22.3%) TKI users had a clinically relevant interaction. The median duration of concomitant prescription was 43 days (IQR = 81), with 91.1% of episodes lasting at least 30 days.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>PPIs and TKIs are frequently prescribed concomitantly in clinical practice. Prescribers should be more cautious when co-prescribing PPIs with TKIs and adapt the dosing regimens when appropriate.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"139 5","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13639104/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149103435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Bone Anabolic Treatment in Patients With Chronic Kidney Disease: A Systematic Review","authors":"Huriye Seyma Kafa, Sabina Chaudhary Hauge, Ditte Hansen","doi":"10.1111/bcpt.70293","DOIUrl":"10.1111/bcpt.70293","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Chronic kidney disease (CKD) associated osteoporosis leads to an increased risk of bone fracture in patients with CKD. Evidence on the efficacy and safety of anti-osteoporotic medications is limited for this group. This systematic review aimed to examine the efficacy and safety of anabolic parathyroid hormone (PTH) treatment in patients with CKD Stages 4–5D.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>MEDLINE, EMBASE and ClinicalTrials.gov were searched systematically for randomized controlled trials (RCTs) investigating teriparatide, natpara, or abaloparatide in adult patients with CKD Stages 4–5D, including kidney transplant recipients. The primary outcome was the change in bone mineral density (BMD) during follow-up measured at the lumbar spine (LS), femoral neck (FN) and total hip (TH). The secondary outcomes included bone turnover markers, fractures, histomorphometric results from bone biopsies and adverse events (AEs).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Two RCTs were included. A subgroup analysis of patients with CKD Stage 4 (<i>n</i> = 5) showed that teriparatide improved BMD at the LS and FN. Another trial (<i>n</i> = 61) in CKD Stage 5D showed significant BMD improvement at the TH compared to the control group. AEs were observed with higher frequency in the teriparatide-treated group.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Treatment with teriparatide seems to improve BMD in patients with CKD Stages 4–5D, but evidence on efficacy and safety is limited.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Trial Registration</h3>\u0000 \u0000 <p>PROSPERO: CRD42024527086</p>\u0000 </section>\u0000 </div>","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"139 5","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13632545/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149103479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mette Østergaard Thunbo, Line Kolding, Samuel Azuz, Terese Matthesen Kamronn, Lene Høimark, Lars Henning Pedersen
{"title":"Antibiotic Use for Cystitis and Risk of Treatment Failure in Pregnancy Following Gastric Bypass: A Cohort Study","authors":"Mette Østergaard Thunbo, Line Kolding, Samuel Azuz, Terese Matthesen Kamronn, Lene Høimark, Lars Henning Pedersen","doi":"10.1111/bcpt.70311","DOIUrl":"10.1111/bcpt.70311","url":null,"abstract":"<p>Cystitis is common during pregnancy and requires effective antibiotic treatment to prevent complications. Gastric bypass surgery alters gastrointestinal anatomy and may impair oral drug absorption, raising concerns about antibiotic effectiveness. We therefore aimed to examine antibiotic use for cystitis and the risk of treatment failure in pregnant women with prior gastric bypass. In this nationwide Danish register-based study, we compared 1985 pregnancies among women with prior gastric bypass with 1 400 174 pregnancies among women without bariatric surgery. We assessed redeemed prescriptions for cystitis-related antibiotics and potential treatment failure defined as repeated antibiotic prescriptions within 14 days, hospital-recorded cystitis or severe urinary tract complications (pyelonephritis or urosepsis). Pregnant women with prior gastric bypass more frequently redeemed cystitis-related antibiotics than those without bariatric surgery (22.6% vs. 12.7%). Among antibiotic-exposed pregnancies, prior gastric bypass was associated with an increased risk of potential treatment failure, including repeated antibiotic prescriptions (adjusted odds ratio [aOR] 1.69, 95% confidence interval [CI] 1.22–2.30) and hospital-recorded cystitis (aOR 2.22, 95% CI 1.24–3.67), while severe complications were rare. These findings suggest that antibiotic treatment may be less effective or that the clinical course is more complicated in this group, highlighting a need for closer monitoring and tailored treatment strategies.</p>","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"139 5","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13632610/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149103509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Abraham García-López, Andrea Guzmán-de Antonio, Tania S. Rubio-Lepe, Elena Diago-Sempere, Juan Raffo-Nogueira, Pedro Arias, Belén Ferrer-Martínez, Sonia Rodriguez-Novoa, Antonio J. Carcas, Irene García-García, Rocío Rosas-Alonso, Alberto M. Borobia
{"title":"Limitations of VKORC1 rs9934438 as a Surrogate Marker for Vitamin K Antagonist Dose Adjustment","authors":"Abraham García-López, Andrea Guzmán-de Antonio, Tania S. Rubio-Lepe, Elena Diago-Sempere, Juan Raffo-Nogueira, Pedro Arias, Belén Ferrer-Martínez, Sonia Rodriguez-Novoa, Antonio J. Carcas, Irene García-García, Rocío Rosas-Alonso, Alberto M. Borobia","doi":"10.1111/bcpt.70312","DOIUrl":"10.1111/bcpt.70312","url":null,"abstract":"<div>\u0000 \u0000 <p><i>VKORC1</i> genetic variants are major determinants of interindividual variability in vitamin K antagonist (VKA) dose requirements and are incorporated into several pharmacogenetic dosing guidelines. The promoter variant rs9923231 is considered the clinically relevant marker for genotype-guided VKA dosing. However, the intronic variant rs9934438 is sometimes used as a surrogate marker because it is assumed to be in strong linkage disequilibrium with rs9923231. We aimed to assess whether rs9934438 can reliably substitute rs9923231 in clinical practice. We conducted a retrospective, single-centre study including 939 patients who underwent pharmacogenetic testing. Both variants were genotyped using a TaqMan OpenArray custom panel. Concordance between rs9934438 and rs9923231 was evaluated, and the diagnostic performance of rs9934438 for predicting clinically relevant rs9923231 diplotypes was assessed. Although concordance was high overall, rs9934438 misclassified two patients who, according to rs9923231, required a reduced VKA dose, resulting in potential false-negative classifications. These findings indicate that, while rs9934438 provides informative results in most cases, it may fail to identify some patients requiring dose adjustment. Our results highlight the clinical implications of relying on surrogate markers in pharmacogenetic-guided VKA therapy and support the preferential use of rs9923231 to ensure accurate individualized dosing and optimize treatment safety.</p>\u0000 </div>","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"139 5","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149103474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Clara Bille, Ken Lund, Jens Kjeldsen, Sareh Kongstad, Per Damkier, Caroline Theilgaard Thorarinsson, Bente Mertz Nørgård
{"title":"Over-the-Counter Analgesics Among Patients With Inflammatory Bowel Disease: A Cross-Sectional Study Based on a New Questionnaire","authors":"Clara Bille, Ken Lund, Jens Kjeldsen, Sareh Kongstad, Per Damkier, Caroline Theilgaard Thorarinsson, Bente Mertz Nørgård","doi":"10.1111/bcpt.70309","DOIUrl":"https://doi.org/10.1111/bcpt.70309","url":null,"abstract":"<div>\u0000 \u0000 <p>Abdominal pain is common in inflammatory bowel disease (IBD) and patients may self-medicate with over-the-counter (OTC) analgesics. We examined OTC analgesic use among adults with IBD in a Danish Gastroenterology outpatient clinic. A questionnaire including demographics, disease characteristics, analgesic types and frequencies, and reasons for use was developed and tested. Overall, 216 patients completed the questionnaire (November 2025–February 2026). Analyses were stratified by IBD type and disease activity; associations were assessed using logistic regression. Over 90% used OTC analgesics, predominantly paracetamol, regardless of IBD type and disease activity. Frequent use (≥ 4 days/week) was more common among patients with disease activity than without within 6 months (16% vs. 6%). Adjusted OR for frequent use within 4 weeks and 6 months were 1.69 (95% CI 0.57–4.99) and 2.37 (95% CI 0.79–7.11), respectively. Among patients with disease activity, 54%, 31% and 12% reported ‘another reasons than IBD’, ‘IBD and another reason’ and ‘IBD’, respectively, as reasons for use. Corresponding proportions without disease activity were 81%, 11% and < 6%, respectively. OTC analgesics use was common regardless of disease activity, but frequent use and IBD-related reasons were more prevalent with disease activity; highlighting the need for clinical awareness and appropriate pain management.</p>\u0000 </div>","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"139 5","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149068403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The 2027 BCPT Perspectives on Studies Involving Natural Products, Traditional Chinese Medicine and Systems Pharmacology","authors":"Pernille Tveden-Nyborg, Baoxue Yang, Gökay Albayrak, Ulf Simonsen, Jens Lykkesfeldt","doi":"10.1111/bcpt.70308","DOIUrl":"https://doi.org/10.1111/bcpt.70308","url":null,"abstract":"<p>Natural products, including isolated compounds, complex extracts, traditional medicinal preparations and marine, microbial, fungal and animal-derived materials, remain important sources of therapeutic agents and pharmacological discovery. However, variation in biological source materials, preparation methods, chemical composition and experimental design may compromise reproducibility and interpretation. This guideline presents the requirements of <i>Basic & Clinical Pharmacology & Toxicology</i> for studies involving natural products and their semisynthetic or biotransformed derivatives. It provides recommendations for documenting scientific and ethnopharmacological rationale, taxonomy, authentication, provenance, sustainable and lawful sourcing, extraction, chemical characterisation, dosing, bioactivity, safety and data accessibility. Particular emphasis is placed on studying the preparation actually administered, using pharmacologically relevant concentrations and doses, controlling vehicle effects and assay interference and aligning mechanistic and therapeutic claims with the supporting evidence. Complex mixtures do not necessarily need to be reduced to a single active constituent; however, their composition must be adequately characterised, and claims concerning individual constituents, additivity, synergy or antagonism require experimental substantiation. Computational, network and systems-pharmacology analyses should be transparent and reproducible, with experimental validation of central predictions. These recommendations apply equivalent standards to natural products and other interventions while recognising the additional information required to define complex biological materials and improve overall translational relevance.</p>","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"139 5","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bcpt.70308","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149068241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}